Equities

Opticept Technologies AB

Opticept Technologies AB

Actions
IndustrialsIndustrial Engineering
  • Price (SEK)2.66
  • Today's Change-0.10 / -3.62%
  • Shares traded37.80k
  • 1 Year change-62.00%
  • Beta1.1488
Data delayed at least 15 minutes, as of Apr 24 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OptiCept Technologies AB, formerly OptiFreeze AB is a Sweden-based company, which provides the food and plant industry with high-tech solutions that contribute to a more sustainable world and enable climate-smart economic growth. OptiCept optimizes biological processes - Increased extraction from the raw material, extended shelf life, reduced waste, and improved quality (taste, aroma, color, nutritional content) of the final product. Through patented technology within PEF (pulsed electric field) and VI (Vacuum Infusion), the technology opens up new business opportunities for the food and plant propagation industry worldwide. OptiCept's purpose is to contribute to a sustainable world by offering efficient green cutting-edge technology that is easy to use in the areas of FoodTech and PlantTech.

  • Revenue in SEK (TTM)9.15m
  • Net income in SEK-80.36m
  • Incorporated2011
  • Employees29.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NextCell Pharma AB12.22m-40.69m87.32m----1.32--7.14-1.18-1.180.35551.920.12414.666.80---41.28-34.92-45.63-37.066.61-68.21-332.90-538.604.97--0.00--80.9672.85-15.21------
Sprint Bioscience AB50.49m-441.00k90.63m28.00--3.2612,946.641.80-0.0064-0.00640.72320.39781.01--7.581,803,036.00-0.8838-71.22-1.58-113.7182.7762.75-0.8735-110.22----0.00--60,725.3022.9999.27---26.02--
Dextech Medical AB0.00-4.57m95.20m1.00--2.95-----0.2473-0.24730.001.750.00-------13.04-28.96-13.21-29.94------------0.00------12.89--0.412--
Annexin Pharmaceuticals AB (publ)0.00-46.41m95.66m4.00--15.08-----0.1887-0.18870.000.01830.00----0.00-256.08-125.42-351.79-151.33------------0.00-------8.17------
Ziccum AB3.75m-21.41m96.64m8.00--10.18--25.79-1.54-1.540.27010.61910.1553--2.01468,375.00-88.74-68.51-109.73-76.47-----571.44-2,598.03----0.0908----75.2025.62---13.45--
Bactiquant A/S19.09m-20.33m99.88m----4.47--5.23-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
Toleranzia AB0.00-7.46m100.51m----0.6547-----0.0597-0.05970.000.7790.00-------5.21-7.45-5.43-7.78------------0.0055------11.79--63.90--
Wntresearch AB0.00-32.47m106.96m2.00--0.6734-----0.1108-0.11080.000.18340.00-------134.87-100.71-166.68-123.59---------------------5.65------
Biosergen AB0.00-27.04m107.41m3.00--9.27-----0.4007-0.40070.000.04180.00----0.00-131.31---217.09----------------------32.25------
Bio-Works Technologies AB43.90m-56.82m109.92m38.00--2.50--2.50-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
Isofol Medical AB (publ)721.00k-37.07m112.74m3.00--0.9284--156.36-0.233-0.2330.00450.75180.0041--0.0728240,333.30-21.15-66.73-26.32-88.27-4,773.37---5,141.61-1,023.62----0.00---94.37--76.80------
Opticept Technologies AB9.15m-80.36m116.49m29.00--0.3166--12.74-2.51-2.510.28448.720.0213-0.06382.37315,344.80-18.69-41.76-21.18-46.20125.8862.65-879.64-882.410.6216-14.160.0566---12.9049.1719.80--45.22--
AlzeCure Pharma AB0.00-37.17m123.24m11.00--5.18-----0.5986-0.59860.000.38290.00----0.00-72.28-52.78-88.22-57.01------------0.00------33.91------
New Nordic Healthbrands AB533.85m-6.20m123.28m73.00--1.16--0.2309-1.00-1.0086.1717.112.131.724.897,313,014.00-2.475.36-5.5510.5565.2367.30-1.162.380.8906-1.150.213847.969.516.28-119.41--28.36--
Enorama Pharma AB1.22m-43.96m126.52m----5.31--103.87-2.16-2.160.04230.43090.03061.070.3212---110.45-64.94-277.27-94.45-267.0886.49-3,609.52-405.420.7249--0.023---37.9634.20-51.50------
SoftOx Solutions AS6.92m-41.73m127.76m--------18.46-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Data as of Apr 24 2024. Currency figures normalised to Opticept Technologies AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.75%Per cent of shares held by top holders
HolderShares% Held
Railroad Ranch Capital Management LPas of 31 Dec 2022317.60k0.75%
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.